Objective-Vascular smooth muscle cells (VSMC) play a key role in the pathogenesis of atherosclerosis, the globally leading cause of death. The transmembrane orphan receptor endosialin (CD248) has been characterized as an activation marker of cells of the mesenchymal lineage including tumor-associated pericytes, stromal myofibroblasts, and activated VSMC. We, therefore, hypothesized that VSMC-expressed endosialin may display functional involvement in the pathogenesis of atherosclerosis. Approach and Results-Expression of endosialin was upregulated during atherosclerosis in apolipoprotein E (ApoE)-null mice and human atherosclerotic samples analyzed by quantitative real-time polymerase chain reaction and immunohistochemistry. Atherosclerosis, assessed by Oil Red O staining of the descending aorta, was significantly reduced in ApoE/endosialin-deficient mice on Western-type diet. Marker analysis of VSMC in lesions induced by shear stressmodifying cast implantation around the right carotid artery identified a more pronounced contractile VSMC phenotype in the absence of endosialin. Moreover, in addition to contributing to neointima formation, endosialin also potentially regulated the proinflammatory phenotype of VSMC as evidenced in surrogate cornea pocket assay experiments in vivo and corresponding flow cytometry and ELISA analyses in vitro. Conclusions-The experiments identify endosialin as a potential regulator of phenotypic remodeling of VSMC contributing to atherosclerosis. The association of endosialin with atherosclerosis and its absent expression in nonatherosclerotic samples warrant further consideration of endosialin as a therapeutic target and biomarker. Visual Overview-An online visual overview is available for this article. stromal myofibroblasts). [14] [15] [16] [17] [18] [19] Importantly, endosialin expression by resting cells in the healthy adult is rather low, 16 compared with its prominent expression by activated cells of the mesenchymal lineage during pathological conditions such as tumor progression, liver fibrosis, and inflammation. 15, 17, 19, 20 Functionally, endosialin regulates mesenchymal cell proliferation through platelet-derived growth factor receptor-β signaling 21, 22 and positively affects cell migration. 14, 17, 23 The role of endosialin during liver fibrosis, lymphoid tissue development, rheumatoid arthritis, and malignancy highlights its function in remodeling and repair processes. [16] [17] [18] We consequently hypothesized that activated VSMCexpressed endosialin may play a role in regulating phenotypic remodeling of VSMC and modulates atherosclerosis progression. We performed toward this end comparative atherosclerosis experiments in wild-type (WT) and endosialin-deficient mice, complemented by expression-profiling experiments of endosialin in human and mouse atherosclerotic lesions. These experiments identified endosialin as a novel marker and potential functional contributor to the pathogenesis of atherosclerosis.
A therosclerosis is an inflammatory disease of the wall of large-and medium-sized arteries that is accompanied by vascular smooth muscle cell (VSMC) proliferation and remodeling. Its progression is initiated by mechanical, biochemical, or immunologic injury to endothelium resulting in endothelial dysfunction. 1 The early stages of atherosclerosis crucially depend on changes of tunica media VSMC, like increased proliferation, migration, and extracellular matrix deposition. 2, 3 Quiescent, contractile VSMC regulate blood vessel diameter (vasodilation and vasoconstriction) in normal mature vessels, whereas pathological vascular remodeling occurs in the tunica intima. 4 
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Inflammation is a major contributor to atherosclerosis and activates the phenotypic switch in VSMC from a contractile to a synthetic phenotype. The phenotypic remodeling of VSMC is in addition to the morphological changes accompanied by distinct alterations in gene expression. Endothelial cells (EC) and VSMC act in concert to maintain this proinflammatory program. Similar to EC, activated VSMC express nuclear factor-κB and inflammation-associated adhesion molecules, like vascular cell adhesion molecule-1, and proinflammatory cytokines and chemokines, such as interleukin (IL)-6, IL-8, CC chemokine ligand (CCL)-2, CCL5, and CX3C chemokine ligand 1. [5] [6] [7] The proinflammatory phenotype of VSMC recruits monocytes/macrophages through secretion of chemokines, which in turn contribute to atherosclerosis. 6, [8] [9] [10] Conversely, recent fate mapping studies have suggested that VSMC of advanced lesions may transdifferentiate to classical VSMC marker-negative macrophage-like cells, which also contribute to the pathogenesis of atherosclerosis. 11, 12 Endosialin (CD248) is a type 1 cell surface glycoprotein that was originally discovered as a putative cell surface receptor of the tumor endothelium. 13 However, high-resolution morphological analyses revealed that endosialin is not expressed by EC but rather by perivascular mural cells (VSMC, pericytes, stromal myofibroblasts). [14] [15] [16] [17] [18] [19] Importantly, endosialin expression by resting cells in the healthy adult is rather low, 16 compared with its prominent expression by activated cells of the mesenchymal lineage during pathological conditions such as tumor progression, liver fibrosis, and inflammation. 15, 17, 19, 20 Functionally, endosialin regulates mesenchymal cell proliferation through platelet-derived growth factor receptor-β signaling 21, 22 and positively affects cell migration. 14, 17, 23 The role of endosialin during liver fibrosis, lymphoid tissue development, rheumatoid arthritis, and malignancy highlights its function in remodeling and repair processes. [16] [17] [18] We consequently hypothesized that activated VSMCexpressed endosialin may play a role in regulating phenotypic remodeling of VSMC and modulates atherosclerosis progression. We performed toward this end comparative atherosclerosis experiments in wild-type (WT) and endosialin-deficient mice, complemented by expression-profiling experiments of endosialin in human and mouse atherosclerotic lesions. These experiments identified endosialin as a novel marker and potential functional contributor to the pathogenesis of atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Endosialin Is Expressed in Atherosclerotic Lesions but Not in Control Vessels
To study the potential contribution of endosialin to atherosclerosis in humans, we analyzed endosialin expression in largevessel specimen of randomly retrieved pathology archive samples. Oil Red O (ORO) staining of supra-and infrarenal aortas and carotid artery identified atherosclerotic lesions in 50% of samples (20 of 40; Figure 1A and 1B). Endosialin was not detectable in any of the ORO-negative samples ( Figure 1A ). Among the ORO-and endosialin-positive samples, 67% were from patients <60 years of age (6 of 9), whereas only 33% were from patients aged 60 to 90 years (3 of 9; Figure 1B ). Of all ORO-positive samples, 90.9% of endosialin-negative samples were from patients in the older age group (10 of 11). In addition, mRNA expression analyses revealed that younger patients (<60 years of age) with atherosclerotic lesions expressed significantly higher levels of endosialin (n=5; P=0.028) as compared with older patients (between 60 and 90 years of age; Figure IA in the online-only Data Supplement). Double immunofluorescence staining for endosialin and α-smooth muscle actin (αSMA) in nonatherosclerotic and atherosclerotic human samples confirmed that endosialin was abundantly expressed by VSMC in atherosclerotic lesions but not on VSMC of samples from healthy patients ( Figure 1A ), whereas overall αSMA content was equal in nonatherosclerotic versus atherosclerotic human samples ( Figure IB in the online-only Data Supplement). Complementing the histochemical analyses, we assessed endosialin mRNA expression in human atherosclerotic lesions and nonatherosclerotic control samples. Nonatherosclerotic arteries showed low to undetectable levels of endosialin mRNA, whereas its expression was significantly upregulated (P=0.007) in samples from atherosclerotic lesions ( Figure 1C) .
We next analyzed endosialin expression in human atherosclerotic samples from large arterial vessels of the lower leg (both, anterior and posterior tibial artery as well as fibular artery) from older patients (>60 years of age) to analyze whether the inverse age-related correlation of atherosclerosis-associated endosialin expression reflected an age-related or an atherosclerotic stage-dependent phenotype. Samples from patients with ruptured advanced lesions (plaques) and signs of active remodeling showed strong focal expression of endosialin. In contrast, endosialin expression in late-stage arteriosclerotic lesions was low or absent. Endosialin expression was not exclusively restricted to the intima because some medial VSMC also expressed endosialin ( Figure 1D ). Collectively, the lower leg sample data in combination with the different age aortic sample data indicate that endosialin expression is primarily a marker of early atherosclerosis progression.
To identify the source of endosialin during atherosclerosis, we assessed endosialin expression in different mesenchymal lineage-derived cell populations (brain pericytes, normal human dermal fibroblasts, human umbilical artery smooth muscle cells, and human aortic smooth muscle cells) and nonmesenchymal cell populations (human umbilical vein endothelial cells, human aortic endothelial cells, and human leukemic monocyte lymphoma cells). These experiments confirmed that endosialin was abundantly expressed at mRNA and protein levels by mural cells but not by nonmural cells ( Figure IIA and IIB in the online-only Data Supplement).
To investigate the correlation of endosialin expression and VSMC phenotype, we performed comparative protein expression analyses of endosialin and the contractile VSMC phenotype markers transgelin, αSMA, and calponin in atherosclerotic human tissue samples. Strikingly, there was a negative correlation of endosialin and transgelin expression with dissociation between younger (<60 years of age) and older patients (60-90 years of age; Figure IIIA and IIIB in the online-only Data Supplement; r=−0.587; n=7). Furthermore, a negative correlation of the contractile markers calponin and αSMA in sequential sections colocalizing with positive endosialin staining in early atherosclerotic samples derived from large arterial vessels of the lower leg was detected ( Figure IIIC in the online-only Data Supplement). Together, the data identify VSMC-expressed endosialin as an early atherosclerosisassociated marker. 
Endosialin-Deficient Mice Display Reduced Atherosclerosis
On the basis of the human expression-profiling experiments, we next analyzed endosialin in atherosclerosis-prone mice using the apolipoprotein E double knockout mice (ApoE −/− ) mouse model. 24, 25 These mice spontaneously develop atherosclerotic lesions, and the complexity of the lesions increases with age and by feeding a cholesterol-rich diet (eg, Western-type diet). Endosialin expression, assessed by quantitative real-time polymerase chain reaction (RT-PCR), was at almost undetectable levels in the ApoE
CD248
+/+ mice (n=8; Figure IVA in the online-only Data Supplement), whereas it was significantly upregulated in aortas of 12-week-old (P=0.005; n=10), 18-week-old (P=0.015; n=9), and 24-week-old (P=0.009; n=10) atherosclerotic ApoE
Cd248
+/+ mice fed a Western-type diet ( Figure 2A ). We next generated constitutive ApoE
−/− double knockout and ApoE
−/−
Cd248
+/+ control female mice, 26 which were fed a Western-type diet for different periods of time (6, 12, 18, and 43 weeks diet). Endosialin deficiency did not affect body weight, plasma cholesterol, and triglyceride concentrations in ApoE-null mice (Table) , whereas there was a reduction in early onset of aortic atherosclerosis with a significant decrease in the ORO-positive area (P=0.019) in 12-weekold endosialin/ApoE-null mice (n=5). This difference was persistently detectable in 18-week-old (P=0.024) (ApoE
, n=18) and 24-week-old mice (P=0.0003; n=8) but not in 49-week-old mice (P>0.7; n=7; Figure 2B and 2C). Measurements of intimal/medial area ratio in 24-week-old mice (P=0.047; n=4) showed that the atherosclerotic lesion areas at aortic arch region of ApoE 
+/+ mice at any stage of atherosclerosis (P>0.4; Figure 2D and 2E), supporting the concept that the rapid changes in the aortic sinus may be more representative of the changes seen in the total aorta at later stages (eg, 49 weeks). 27 Taken together, the genetic mouse experiments further validated endosialin as a marker of atherosclerosis and identified an important role of endosialin in the onset and progression of atherosclerosis.
To study the contribution of endosialin expressed by VSMC in atherosclerotic lesion progression in a second complementary animal model, we implanted a flow-modifying and thereby shear stress-modifying cast around the right carotid artery of ApoE
−/− and control ApoE
mice to generate atherosclerotic lesions. 28 The left carotid artery served as a control in these experiments (Figure VA 
Endosialin Balances the Contractile and Synthetic VSMC Phenotype
Cross-sections of the carotid arteries of cast-implanted mice (24 weeks old) euthanized 12 weeks after implantation were stained for EC (CD31) and contractile VSMC markers (αSMA, calponin; n=6; Figure 3A ). In the absence of endosialin, the αSMA-(P=0.022) and calponin-positive (P=0.034) areas in the intima were increased at regions downstream of the cast ( Figure 3B and 3C Figure IXA and IXB in the online-only Data Supplement).
We next isolated VSMC from 18-week Western-type diet-fed ApoE −/− Cd248 −/− and ApoE −/− Cd248 +/+ mice (24 weeks old) and analyzed them after short-term culture. The purity of isolated VSMC was validated by abundant Pdgfrb (platelet-derived growth factor receptor-b) and Desmin expression and almost undetectable levels of the EC transcript Pecam (platelet endothelial cell adhesion molecule-1) and the fibroblast transcript S100A4 ( Figure XA and XB in the online-only Data Supplement). VSMC were stained for contractile VSMC-specific markers and analyzed. αSMA-positive (P=0.026) and calponin-positive area per 
Cd248
+/+ mice (n=6). The positive staining in the tunica media was excluded during quantification. Values are mean±SD. *P≤0.05, **P≤0.01, ***P≤0.001. ApoE indicates apolipoprotein E; n, number of animals; and n.s., nonsignificant.
cell (P=0.019) was significantly higher in isolated cells from aortas of ApoE −/− Cd248 −/− mice compared with those from ApoE −/− Cd248 +/+ mice (n=4) at passage 1 ( Figure 4C and 4D). Furthermore, isolated VSMC from atherosclerosis-challenged endosialin-null mice at passage 0 (n=4) expressed significantly increased mRNA levels of the contractility markers Acta2 (P=0.035), Cnn1 (P=0.001), Sm-mhc (P=0.001), and Myo (P=0.006) and significantly decreased levels of the synthetic markers Myh10 (P=0.013), Vim (P=0.002), Rbp1 (P=0.042), and Mgp (P=0.001; Figure 4E and 4F). Transcript levels of other contractile and synthetic VSMC marker were unaltered ( Figure XIA and XIB in the online-only Data Supplement). The contractile VSMC marker αSMA was also significantly increased (P=0.031) at the protein level, whereas the proliferating cell nuclear antigen expression was significantly decreased (P=0.008) in isolated VSMC from 24-week-old ApoE −/− Cd248 −/− mice (n=6) on a Western-type diet ( Figure XIIA in the online-only Data Supplement). Gene expression of cFos, a gene involved in proliferation, was also significantly reduced (P=0.005) in isolated VSMC from ApoE −/− CD248 −/− mice (n=6), whereas there were no significant changes in gene expression of apoptosis-related genes in the presence and absence of endosialin in VSMC isolated from atherosclerotic ApoE knockout mice (n=3; Figure XIIB and XIIC in the online-only Data Supplement).
Platelet-derived growth factor bb (PDGFBB) has been shown to suppress the expression of contractile VSMC-specific genes. 30, 31 Concentrations of circulating Pdgfbb and Pdgfbb gene expression in aortas of atherosclerotic mice were not altered in the presence and absence of endosialin in ApoE-null mice ( Figure XIII in the online-only Data Supplement). To further study the relationship between PDGFBB, endosialin, and the contractile phenotype, we stimulated primary human aortic smooth muscle cells at different passages (2, 4, and 6) with PDGFBB. Significantly increased endosialin (FB5; P=0.049) and significantly decreased αSMA-positive (P=0.029) and calponin-positive (P=0.047) areas per cell were observed in human aortic smooth muscle cells on stimulation with PDGFBB (25 ng/mL; 8 hours; Figure XIVA through XIVC in the online-only Data Supplement). Together, the results establish a role of endosialin in shifting the balance toward a more synthetic VSMC phenotype.
Endosialin Deficiency Reduces Macrophage Accumulation
Atherosclerosis is strongly associated with inflammation. We, therefore, set out experiments aimed at studying the potential contribution of endosialin to the inflammatory changes associated with atherosclerosis. Considering recent findings that atherosclerosis-associated myeloid infiltrates could be derived from smooth muscle cells, 11, 12 we opted to do atherosclerosisunrelated surrogate experiments. We performed toward this end comparative cornea pocket assays in WT and endosialin knockout mice. A combination of lipopolysaccharides (a proinflammatory stimulus) and PDGFBB (a stimulus for VSMC proliferation and migration) was implanted as slow release pellet in the avascular mouse cornea. Implantation of either lipopolysaccharide or PDGFBB alone did not cause a significant difference in macrophage recruitment ( Figure XV in the online-only Data Supplement; n=5; assessed as percentage of F4/80-positive area normalized to total area). In contrast, coimplanting PDGFBB and lipopolysaccharide resulted in significantly enhanced macrophage recruitment in WT mice compared with endosialin-deficient mice (Figure 5A and 5B; P=0.015, n=5), indicating an involvement of endosialin in immune cell recruitment.
To translate the results of these surrogate experiments to atherosclerotic lesions, we next performed flow cytometry of cells isolated from atherosclerotic aortas from 18-week-old ApoE
Cd248
−/− and ApoE −/− Cd248 +/+ mice. In the absence of endosialin, the percentage of the CD45+ CD11b+ F4/80+ macrophage subpopulation (P=0.042; n=5) was significantly reduced after 12-week Western-type diet ( Figure 5C and 5D ). The reduction of macrophage content in the atherosclerotic lesions of endosialin-deficient mice was further validated by gene expression analysis. Quantitative RT-PCR of total aortas from atherosclerosis-challenged 24-week-old ApoE
−/− (n=8) and ApoE −/− Cd248 +/+ mice (n=6) on a Western-type diet for 18 weeks revealed a significant decrease in Cd68 gene expression in the absence of endosialin ( Figure  6A; P≤0.01) . Correspondingly, we identified a significant reduction of chemokine receptor expression, including Ccr2 (P=0.015), Ccr5 (P=0.033), and Cx3cr1 (P=0.026) and a significant decrease of corresponding ligand expression including Ccl2 (P=0.045), Ccl5 (P=0.009), and Cx3cl1 (P=0.02; 
+/+ mice on a Western-type diet for 18 wk. F, Representative images of DAPI-stained macrophages (blue), which transmigrate toward VSMC medium (control) or supernatant collected from isolated and stimulated aortic VSMC from Cd248
and Cd248 −/− mice. Bar=200 µm. G, Representative Transwell chamber scheme of isolated bone marrow macrophages migrating from upper chamber toward the supernatant collected from stimulated VSMC in the lower chamber. H, Number of macrophages (P=0.044) transmigrated toward the supernatant collected from isolated and stimulated aortic VSMC form Cd248 +/+ and Cd248 −/− mice (n=3) on stimulation with tumor necrosis factor-α (TNFα; 5 ng/mL; 24 h). The quantification of transmigrated macrophages was performed in 6 fields per condition of 3 independent experiments. Three independent experiments were performed in triplicates. I, Gene expression analysis of isolated aortic VSMC from Cd248 +/+ and Cd248 , n=12) in the absence of endosialin in 24-week-old ApoE-null mice on a westerntype diet for 18 weeks ( Figure 6D and 6E) . Furthermore, isolated VSMC from Cd248 −/− and WT mice that were stimulated with 5 ng/mL tumor necrosis factor-α for 24 hours displayed a reduction in Ccl2 and Ccl5 release on endosialin deficiency ( Figure XVIII in the online-only Data Supplement).
To mechanistically validate the in vivo findings in vitro, we performed Transwell invasion assays of macrophages, in which macrophages migrated toward supernatants collected from isolated and stimulated VSMC from atherosclerotic ApoE Figure 6I, n=3) . These results suggest that endosialin contributes to macrophage influx into the intima by regulating the proinflammatory phenotype of VSMC during atherosclerosis.
Discussion
Endosialin is an oncofetal mesenchymal cell activation marker that is abundantly expressed by pericytes, tumor-associated stromal myofibroblasts, and activated VSMC during tumor angiogenesis. 13, 14, 16, 19 Regarding this unique expression pattern, we hypothesized that endosialin may affect the function of activated VSMC during atherosclerosis. On the basis of 2 complementary mouse models (aorta analysis and arteria carotis cast implantation) and human tissue expression-profiling experiments, we show here that (1) endosialin is upregulated in atherosclerotic samples from mice and men, (2) atherosclerosis onset and progression is delayed in endosialin-deficient mice, (3) endosialin deficiency supports the contractile VSMC phenotype, and (4) endosialin contributes to inflammatory progression through the regulation of VSMC-specific chemokine release.
The expression of endosialin in human atherosclerotic lesions and in experimental mouse models of atherosclerosis solidly establishes endosialin as a novel marker of atherosclerosis. Strikingly, albeit based on a small cohort of samples, expression was particularly prominent in younger patients (<60 years of age) and in samples from older patients with signs of active remodeling. This may correspond to the finding that endosialin affected atherosclerosis in mice at earlier stages (12, 18 , and 24 weeks) but not at later stages (49 weeks). Coinciding with this finding, an inverse correlation of endosialin expression and age was previously identified in a study of patients with grade II to IV astrocytomas. 32 Together, these findings suggest a role of endosialin in the pathogenesis of atherosclerosis, particularly affecting the early stages of disease progression.
Functionally, atherosclerosis experiments in endosialindeficient mice (ApoE/endosialin double knockout mice on Western-type diet) revealed a reduction of early disease progression with formation of less severe lesions. In contrast to total aorta, endosialin deficiency in ApoE-null mice did not affect the speed of atherosclerotic lesion formation in the aortic sinus. The analyzed time points in this study of atherosclerotic lesions in the aortic sinus may be more representative of lesion progression seen at later stages in the aorta. That may be explained by anatomic differences, different shear stress conditions with a complex and turbulent blood flow, a different set of gene expression in the aortic sinus, 33 and differential roles of VSMC depending on the stage of disease progression. Therefore, the anatomic and pressure differences of the sinus compared with the distal aorta may have contributed to the differential effects observed in endosialindeficient mice.
The resistivity index of an atherosclerotic vessel, which reflects vessel wall extensibility and resistance, is an important hemodynamic predictor of cardiovascular mortality. 33 Increased resistivity index in common carotid arteries of shear stress-modifying cast-implanted endosialin-deficient ApoEnull mice is consistent with the observed correlation between carotid bed resistivity index and the degree of atherosclerosis in patients. 34 Comparative gene expression-profiling experiments identified a role of endosialin in the regulation of VSMC phenotypic remodeling at early stages of atherosclerosis. Experiments in the arteria carotis cast-implantation model proved particularly useful toward this end: the lower shear stress upstream of the cast induces lesions with characteristics of a vulnerable plaque, whereas the area downstream of the cast develops lesions with characteristics of a stable plaque. 21 The contractile VSMC markers αSMA and calponin were significantly upregulated downstream but not upstream of the cast in atherosclerosis-challenged endosialin-deficient mice, indicating a role of endosialin in the regulation of a mature contractile versus the synthetic VSMC phenotype during early atherosclerotic lesion formation. Consistent with this view, endosialin deficiency in ApoE-null mice reduced lesion area and delayed the severity of atherosclerosis in the regions downstream of the cast. These data are in line with our observations above that demonstrate a significant delay of disease progression at early stages in the absence of endosialin in total aortas of ApoE-null mice.
Analysis of additional contractile and synthetic VSMCspecific marker genes 4 in vivo and in vitro confirmed the role of endosialin as a player in balancing the synthetic versus the contractile VSMC phenotype, but further gain-of-function or loss-of-function experiments will be necessary to fully elucidate the mechanism. Similar to our finding in mice, endosialin expression negatively correlated with the expression of the VSMC contractility marker transgelin in human atherosclerotic samples particularly in younger patients (<60 years). These findings suggest that endosialin could be a relevant regulator of phenotypic VSMC remodeling and might in the future be considered as an attractive therapeutic target to inhibit the switch between contractile and synthetic VSMC phenotypes.
In addition to controlling VSMC phenotypic remodeling, endosialin also showed immune-modulatory effects. The reduced atherosclerosis in ApoE/endosialin-deficient mice was consistent with a marked reduction of macrophages in these lesions. We performed surrogate cornea pocket experiments aimed at unraveling the role of endosialin during nonatherosclerosis-induced inflammation. Again, the significant reduction of macrophage recruitment in the absence of endosialin in these experiments suggested a general role of endosialin in controlling inflammatory gene expression independent of atherosclerosis-induced inflammation. The results of these surrogate model experiments most likely exclude a role of endosialin in the transdifferentiation of VSMC into macrophage-like cells as has been shown by lineage-tracing experiments. 11, 12 Additionally, flow cytometric analyses of cells isolated from early-stage atherosclerotic aortas (18 weeks) revealed reduced F4/80-positive macrophages in ApoE −/−
Cd248
−/− mice, suggesting a role of endosialin in controlling the proinflammatory phenotype of VSMC. Indeed, corresponding analyses of isolated VSMC support a role of VSMC in regulating the local inflammatory milieu through the release of macrophage-recruiting chemokines. 7 Isolated VSMC from endosialin-deficient mice showed significantly reduced expression of Ccl2, Ccl5, and Cx3cl1 mRNA both in vivo and in vitro, which also impaired macrophage transmigration. Correspondingly, circulating levels of Ccl2 and Ccl5 were reduced in atherosclerosis-challenged endosialin-deficient mice. Taken together, these data suggest a role of endosialin in shaping the inflammatory milieu in atherosclerotic lesions by regulating VSMC inflammatory gene expression.
In summary, the experiments of this study provide evidence for a role of endosialin in VSMC phenotypic remodeling and inflammation in atherosclerotic lesions. Our results show that endosialin is upregulated in human and mouse atherosclerotic samples and suggest that endosialin shifts the balance toward a synthetic and proinflammatory phenotype of VSMC and, thus, contributes to increased proliferation of VSMC and numbers of macrophages during disease progression ( Figure  XX in the online-only Data Supplement). The strong association of endosialin with pathologies involving activated mesenchymal cells including atherosclerosis (this study), fibrosis, 17 and tumor progression 16 make endosialin an attractive therapeutic target. An antihuman (albeit not mouse cross-reacting) endosialin-neutralizing antibody (MORab-004) is in clinical development for the treatment of mesenchymal cell-derived tumors (www.clinicaltrials.gov/ct2/results?term=endosialin& Search=Search). The findings of this study strongly warrant a consideration of endosialin as a therapeutic target outside the field of oncology.
